DIT101 therapy for blood cancers that have not responded to treatment
Part of Blood & lymphatic, Cancer clinical trials.
This study tests an experimental treatment called DIT101 for people with blood cancers that have returned or not responded to standard therapy. It aims to see if the treatment is safe and effective for your type of cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 69 years old.
- You have a type of blood cancer (like leukemia or lymphoma) that has come back or hasn't gone away after treatment.
- The cancer cells must have a specific protein on them that this therapy targets.
- You must be reasonably physically active (able to take care of yourself).
- Your vital organs (kidneys, liver, heart, lungs) need to be working well enough.
- You must not have untreated or uncontrolled leukemia in the brain or spinal fluid.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether CAR-T cells, a type of immunotherapy that targets specific markers on cancer cells, can treat blood cancers that have come back or not responded to standard treatment. It may offer a new option for people with lymphoma, leukemia, or multiple myeloma.
This trial tests a new type of CAR-T cell therapy that is engineered to be more effective against a specific kind of leukemia (B-ALL) that has returned or not responded to treatment. The therapy uses a patient's own immune cells to target and destroy cancer cells.
This early-phase trial tests an injected “CAR T” cell therapy made to attack CD19-positive blood cancers that have come back or did not respond. If you qualify, the study checks whether the treatment can help control the cancer and is safe enough to study further.
This trial tests a new CAR-T cell therapy for people with certain blood cancers (B-cell acute lymphoblastic leukemia, B-cell lymphoma, or multiple myeloma) that have come back or stopped responding to treatment. The therapy uses your own immune cells, modified in a lab to attack cancer cells, then given back to you intravenously.
This trial tests a new type of immunotherapy called CAR-T cells, which are made from your own blood cells and trained to find and destroy leukemia cells. It is for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments.
This study tests a new CAR-T cell therapy called DuoCAR20.19.22-D95 for people with certain blood cancers (like lymphoma and ALL) that have come back or haven't responded to multiple treatments. It aims to see if this therapy is safe and can help shrink or control the cancer.
Hear when a new Relapsed or Refractory Hematologic Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.